Frontier Medicines is a pre-clinical stage biopharmaceutical company that is pioneering breakthrough technologies to drug the “undruggable” proteome. Frontier Medicines’ proprietary platform uses chemoproteomics – an innovative approach to chemically interrogate proteins in living systems – to discover and pharmacologically target new binding pockets (or hotspots) on proteins for the purpose of making them accessible to therapeutic intervention. Our therapeutic programs are focused on some of the most important and difficult targets in human disease, starting with cancer, in order to change the lives of patients for the better. As a Fierce 15 company FierceBiotech recognized Frontier as one of the most promising private biotechnology companies in the industry.
